Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ledipasvir; Ribavirin
- Indications Liver cirrhosis
- Focus Therapeutic Use
- 05 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Oct 2017.
- 05 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Sep 2017.
- 05 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.